Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

Juan Du, Wanting Qiang, Jing Lu, Yanchun Jia, Haiyan He, Jin Liu, Pei Guo, Ying Yang, Zhongyuan Feng, Lina Jin, Xiaoqiang Fan, Jia Liu, Qi Zhang, Lianjun Shen, Lihong Weng, Wenling Li, Wei Cao

Blood (2023) 142 (Supplement 1): 1022.

https://doi.org/10.1182/blood-2023-174841

Published: 2023

Journal Articles

Minimal Residual Disease in Acute Myeloid Leukemia Following Induction Chemotherapy Can be Effectively Eradicated By Targeting Mitochondrial Metabolism

Blood (2023) 142 (Supplement 1): 2952.

https://doi.org/10.1182/blood-2023-186514

Published: 2023

Journal Articles

ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Inhibiting Drp1 Dependent Mitochondrial Fission

Priyanka Sharma, Lauren B. Ostermann, Sujan Piya, Baozhen Ke, Natalia Baran, Anudishi Tyagi, Muharrem Muftuoglu, Mahesh Basyal, Qi Zhang, Joanne Munck, Kim-Hien Dao, Martin Sims, Bing Z. Carter, Venkata Lokesh Battula, Michael Andreeff, Gautam Borthakur

Blood (2023) 142 (Supplement 1): 412.

https://doi.org/10.1182/blood-2023-185700

Published: 2023

Journal Articles

Combination of Selinexor with BTK Inhibitor for Central Nervous System Diffuse Large B-Cell Lymphoma, Possible Mechanisms and Therapeutic Potential Exploration

Li Li, Wenjing Yang, Ruyu Ye, Yuanyuan Pan, Qi Zhang, Bo Tang, Xiaobo Wang

Blood (2023) 142 (Supplement 1): 3010.

https://doi.org/10.1182/blood-2023-184371

Published: 2023

Journal Articles

Venetoclax Synergizes with IMGN632, a Novel CD123-Targeting Antibody Conjugated to a DNA Alkylating Payload, By Suppressing DNA Damage Response and Potentiating Apoptosis in Acute Myeloid Leukemia in Vitro Models

Anna Skwarska, Vinitha Mary Kuruvilla, Qi Zhang, Sovira Chaudhry, Naval Daver, Krystal Watkins, Callum Mortimer Sloss, Patrick A. Zweidler-McKay, Deepa Sampath, Marina Y. Konopleva

Blood (2023) 142 (Supplement 1): 4155.

https://doi.org/10.1182/blood-2023-187018

Published: 2023

Journal Articles

Targeting BCL-XL with a Novel VHL-Based BCL-XL Degrader DT-2216 in Pre-Clinical JAK2 -Mutant AML Post-MPN Models

Zhe WANG, Qi Zhang, Anna Skwarska, Cassandra L. Ramage, Guangrong Zheng, Kira Gritsman, Kapil N. Bhalla, Naveen Pemmaraju, Daohong Zhou, Jeffrey W Tyner, Marina Y. Konopleva

Blood (2023) 142 (Supplement 1): 4154.

https://doi.org/10.1182/blood-2023-178813

Published: 2023

Journal Articles

Efficacy and Safety of Selinexor-Based Combination Therapy in CNS Lymphoma: A Retrospective Experience

Li Li, Yan Ma, Xiaobo Wang, Zhiming Li, Zhiguang Lin, Qi Zhang, Jay Mei, Jingjing Ma, Xin Gao, Hui Kang, Zhijia Zhao, Hang Yang, Qing Li, Mengxue Zhang, Yingbo Zhou, Bobin Chen

Blood (2023) 142 (Supplement 1): 6301.

https://doi.org/10.1182/blood-2023-184682

Published: 2023

Journal Articles

Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia

Qi Zhang, He Li, Xuelan Chen, Fan Gu, Lanxin Zhang, Lu Zhang, Tong Chen, Qiang Chen, Wentong Meng, Yu Wu, Hong Chang, Ting Liu, Chong Chen, Hongbing Ma, Yu Liu

Blood (2023) 142 (17): 1494–1499.

https://doi.org/10.1182/blood.2023020619

Published: 2023

Includes: Supplemental data

Journal Articles

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

Blood (2023) 141 (13): 1610–1625.

https://doi.org/10.1182/blood.2021011094

Published: 2023

Includes: Supplemental data

Journal Articles

Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 101–103.

https://doi.org/10.1182/blood-2022-158694

Published: 2022

Journal Articles

CRISPR/Cas9 Genome-Edited Autologous Hematopoietic Stem Cell Transplantation Therapies for Sickle Cell Disease

Yi Liu, Vionnie W. Yu, Qi Zhang, Madhura Panditrao, Yi Yang, Alberto Del Rio-Espinola, Daher Ibrahim Aibo, Azeddine Elhajouji, Konrad Mueller, Karin Abitorabi, Daniel O'Connell, Bo Han, Nishit Patel, Carsten Russ, Craig Mickanin, Timothy K. MacLachlan, Susan C. Stevenson

Blood (2022) 140 (Supplement 1): 12982–12983.

https://doi.org/10.1182/blood-2022-159892

Published: 2022

Journal Articles

Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells

Yannan Jia, Lina Han, Cassandra L Ramage, Connie C. Weng, Lei Yang, Simona Colla, Helen Ma, Weiguo Zhang, Michael Andreeff, Naval Daver, Nitin Jain, Naveen Pemmaraju, Kapil N. Bhalla, Satu Mustjoki, Peiyi Zhang, Guangrong Zheng, Daohong Zhou, Qi Zhang, Marina Konopleva

Blood (2022) 140 (Supplement 1): 3347–3349.

https://doi.org/10.1182/blood-2022-164541

Published: 2022

Journal Articles

Multiple Myeloma Evolution Is Characterized By Dynamic Epigenetic Landscapes

Rafael Renatino-Canevarolo, Mark B. Meads, Maria L. Coelho Siqueira Silva, Praneeth Reddy Sudalagunta, Christopher Cubitt, Gabriel De Avila, Raghunandan Reddy Alugubelli, Amit Kulkarni, Qi Zhang, Oliver Hampton, Rachid C. Baz, Kenneth H. Shain, Ariosto Siqueira Silva

Blood (2022) 140 (Supplement 1): 3036–3037.

https://doi.org/10.1182/blood-2022-163511

Published: 2022

Journal Articles

Phase I Open-Label Single-Arm Study of BCMA/CD19 Dual-Targeting FasTCAR-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

Juan Du, Weijun Fu, Jing Lu, Wanting Qiang, Haiyan He, Jin Liu, Ying Yang, Zhongyuan Feng, Lina Jin, Xiaoqiang Fan, Jia Liu, Qi Zhang, Lianjun Shen, Lihong Weng, Wei Cao

Blood (2022) 140 (Supplement 1): 889–890.

https://doi.org/10.1182/blood-2022-162295

Published: 2022

Journal Articles

EZH2 Inhibition Mediates Proptosis Via DHX9 and S100A9 in Myelodysplastic Syndromes

Qi Zhang, Wei Lang, Lu Wang, Wenli Yang, Yingwan Luo, Shuanghong Zhu, Lingxu Jiang, Yuxia Wang, Chen Mei, Xinping Zhou, Yanling Ren, Liya Ma, Li Ye, Xingnong Ye, Gaixiang Xu, Jie Sun, Jie Jin, Hongyan Tong

Blood (2022) 140 (Supplement 1): 9767–9768.

https://doi.org/10.1182/blood-2022-165886

Published: 2022

Journal Articles

FLT3 Inhibitors Upregulate CXCR4 and E-Selectin Ligands and CD44 Via ERK Suppression in AML Cells, and Blockade of CXCR4 and E-Selectin Signaling with GMI-1359 Overcomes AML Resistance to Quizartinib in Vitro and In Vivo

Yannan Jia, Mahesh Basyal, Lauren B Ostermann, Kyung Hee Chang, Qi Zhang, William E. Fogler, John L. Magnani, Marina Konopleva, Weiguo Zhang, Michael Andreeff

Blood (2021) 138 (Supplement 1): 1171.

https://doi.org/10.1182/blood-2021-146573

Published: 2021

Journal Articles

Combined Blockade of CD47-Sirpa Interaction By 5F9 (Magrolimab) and Azacitidine/Venetoclax Therapy Facilitates Macrophage-Mediated Anti-Leukemia Efficacy in AML Pre-Clinical Models

Yannan Jia, Qi Zhang, Connie Weng, Cassandra L Ramage, Yuki Nishida, Mark Chao, Roy Louis Maute, Shelley Herbrich, Weiguo Zhang, Michael Andreeff, Naval Daver, Marina Konopleva

Blood (2021) 138 (Supplement 1): 510.

https://doi.org/10.1182/blood-2021-147479

Published: 2021

Journal Articles

Targeting BCL-XL and BCL-2 By Protac 753B Effectively Eliminates AML Cells and Enhances Efficacy of Chemotherapy By Targeting Senescent Cells

Yannan Jia, Qi Zhang, Weiguo Zhang, Michael Andreeff, Nitin Jain, Peiyi Zhang, Guangrong Zheng, Daohong Zhou, Marina Konopleva

Blood (2021) 138 (Supplement 1): 2230.

https://doi.org/10.1182/blood-2021-147535

Published: 2021

Journal Articles

Combination Therapy of FLT3 Tyrosine Kinase Inhibitors and BH3 Mimetics Targeting Antiapoptotic MCL-1 Synergistically Eliminates FLT3-ITD Acute Myeloid Leukemia Cells in Vitro and In Vivo

Blood (2021) 138 (Supplement 1): 2248.

https://doi.org/10.1182/blood-2021-151042

Published: 2021

Journal Articles

Combining IMGN632, a Novel CD123-Targeting Antibody Drug Conjugate with Azacitidine and Venetoclax Facilitates Apoptosis in Vitro and Prolongs Survival In Vivo in AML Models

Vinitha Mary Kuruvilla, MSc, Qi Zhang, PhD, Naval Daver, MD, Krystal Watkins, Callum M Sloss, PhD, Patrick A Zweidler-McKay, MDPhD, Angela Romanelli, PhD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136791

Published: 2020

NARROW

Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

Minimal Residual Disease in Acute Myeloid Leukemia Following Induction Chemotherapy Can be Effectively Eradicated By Targeting Mitochondrial Metabolism

ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Inhibiting Drp1 Dependent Mitochondrial Fission

Combination of Selinexor with BTK Inhibitor for Central Nervous System Diffuse Large B-Cell Lymphoma, Possible Mechanisms and Therapeutic Potential Exploration

Venetoclax Synergizes with IMGN632, a Novel CD123-Targeting Antibody Conjugated to a DNA Alkylating Payload, By Suppressing DNA Damage Response and Potentiating Apoptosis in Acute Myeloid Leukemia in Vitro Models

Targeting BCL-XL with a Novel VHL-Based BCL-XL Degrader DT-2216 in Pre-Clinical JAK2 -Mutant AML Post-MPN Models

Efficacy and Safety of Selinexor-Based Combination Therapy in CNS Lymphoma: A Retrospective Experience

Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia

CRISPR/Cas9 Genome-Edited Autologous Hematopoietic Stem Cell Transplantation Therapies for Sickle Cell Disease

Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells

Multiple Myeloma Evolution Is Characterized By Dynamic Epigenetic Landscapes

Phase I Open-Label Single-Arm Study of BCMA/CD19 Dual-Targeting FasTCAR-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

EZH2 Inhibition Mediates Proptosis Via DHX9 and S100A9 in Myelodysplastic Syndromes

FLT3 Inhibitors Upregulate CXCR4 and E-Selectin Ligands and CD44 Via ERK Suppression in AML Cells, and Blockade of CXCR4 and E-Selectin Signaling with GMI-1359 Overcomes AML Resistance to Quizartinib in Vitro and In Vivo

Combined Blockade of CD47-Sirpa Interaction By 5F9 (Magrolimab) and Azacitidine/Venetoclax Therapy Facilitates Macrophage-Mediated Anti-Leukemia Efficacy in AML Pre-Clinical Models

Targeting BCL-XL and BCL-2 By Protac 753B Effectively Eliminates AML Cells and Enhances Efficacy of Chemotherapy By Targeting Senescent Cells

Combination Therapy of FLT3 Tyrosine Kinase Inhibitors and BH3 Mimetics Targeting Antiapoptotic MCL-1 Synergistically Eliminates FLT3-ITD Acute Myeloid Leukemia Cells in Vitro and In Vivo

Combining IMGN632, a Novel CD123-Targeting Antibody Drug Conjugate with Azacitidine and Venetoclax Facilitates Apoptosis in Vitro and Prolongs Survival In Vivo in AML Models

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only